Page 1

( Mark One ) ☑ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D.C. 20549 FORM 10 - K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31 , 2020 or ㅁ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number : 001-38634 REVIVA PHARMACEUTICALS HOLDINGS , INC . ( Exact name of registrant as specified in its charter ) Delaware ( State or other jurisdiction of incorporation or organization ) 19925 Stevens Creek Blvd. , Suite 100 Cupertino , CA 95014 ( Address of principal executive offices ) ( 408 ) 501-8881 ( Registrant's telephone number , including area code ) 85-4306526 ( I.R.S. Employer Identification Number ) 95014 ( Zip code ) Securities registered pursuant to Section 12 ( b ) of the Act : Title of Each Class : Common Stock , par value $ 0.0001 per share Trading Symbol RVPH Name of Each Exchange on which Registered The Nasdaq Capital Market Warrants to purchase one share of Common Stock RVPHW The Nasdaq Capital Market Securities registered pursuant to Section 12 ( g ) of the Act : None Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes □ No ☑ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . Yes □ No Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes > No □